Target intelligence / Profile preview

Potassium voltage-gated channel subfamily Q member x (KCNQx)

Target
KCNQx
Molecular classification
Ion channel, Voltage-gated potassium channel, Transmembrane protein
01

Overview

Potassium voltage-gated channel subfamily Q members are a group of transmembrane proteins that form part of the family of voltage-gated potassium channels, essential for setting and shaping the electrical signals in neurons, heart and muscle cells. Each member (KCNQ1–KCNQ5) has distinct tissue distributions and physiological roles, including cardiac action potential repolarization (KCNQ1), regulation of neuronal excitability and transmission (KCNQ2, KCNQ3), auditory function (KCNQ4), and contributions to skeletal muscle function (KCNQ5). They can form both homomultimeric and heteromultimeric channels, producing the "M-current" in neurons, and are targeted by several drugs for neurological, cardiac, or sensory disorders. Note: The target name "Potassium voltage-gated channel subfamily Q member x" is not canonical and should be replaced with a specific member designation for structured mapping, e.g., "Potassium voltage-gated channel subfamily Q member 1 (KCNQ1)" for cardiac-specific functions, "Potassium voltage-gated channel subfamily Q member 2 (KCNQ2)" for neuronal roles, etc.

Other names
Potassium channel, voltage-gated subfamily QKv7.xKCNQxKvLQT
02

Mechanism of action

Potassium channel opener (activates potassium efflux, stabilizing membrane potential); Potassium channel blockade/inhibition (suppresses M-current, increases excitability)

03

Biological functions

Electrical signal propagation in excitable cells (neurons, muscle)Regulation of neuronal excitabilityMaintenance of cardiac action potentialM-current generation in neuronsAuditory signal transduction (in case of KCNQ4)
04

Disease associations

Neurodegenerative disease (e.g., epilepsy for KCNQ2/3)Hearing loss (KCNQ4)Cardiovascular disease, especially arrhythmias (KCNQ1)Other (depending on specific member)
05

Safety considerations

Cardiac arrhythmias (QT prolongation for KCNQ1 modulators)Potential for CNS effects (seizures, cognitive impact)Hearing loss (for KCNQ4 mutations)
06

Interacting drugs

Retigabine (ezogabine; KCNQ2/3 opener, anti-convulsant)

3 more in the full profile.

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily Q member x (KCNQx).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily Q member x (KCNQx).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call